Clinical trial
Capecitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer
NCT00258284 · Barbara Ann Karmanos Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00258284 |
|---|---|
| Title | Capecitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer |
| Official title | Phase II Trial of Capecitabine (Xeloda) and Weekly Docetaxel (Taxotere) in Metastatic Androgen Independent Prostate Carcinoma |
| Lead sponsor | Barbara Ann Karmanos Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | capecitabine, docetaxel |
| Enrollment | 30 |
| Start date | Aug 1, 2003 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Nov 24, 2005 |
| Last update posted | Mar 6, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: